243 related articles for article (PubMed ID: 21909350)
1. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.
Wang WY; Zhang J; Wu WY; Li J; Ma YL; Chen WH; Yan H; Wang K; Xu WW; Shen JH; Wang YP
PLoS One; 2011; 6(8):e23425. PubMed ID: 21909350
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
Hu MM; Zhang J; Wang WY; Wu WY; Ma YL; Chen WH; Wang YP
Acta Pharmacol Sin; 2011 Oct; 32(10):1253-8. PubMed ID: 21970837
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2.
Zhang H; Zhang JY; Sun TW; Shen DL; He F; Dang YH; Li L
Clin Invest Med; 2013 Feb; 36(1):E32-41. PubMed ID: 23374598
[TBL] [Abstract][Full Text] [Related]
4. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
5. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral-mediated RNA interference of lipoprotein-associated phospholipase A2 ameliorates inflammation and atherosclerosis in apolipoprotein E-deficient mice.
Zhang H; Zhang J; Shen D; Zhang L; He F; Dang Y; Li L
Int J Mol Med; 2013 Mar; 31(3):651-9. PubMed ID: 23338278
[TBL] [Abstract][Full Text] [Related]
7. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
8. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M
Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664
[TBL] [Abstract][Full Text] [Related]
9. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial.
Johnson JL; Shi Y; Snipes R; Janmohamed S; Rolfe TE; Davis B; Postle A; Macphee CH
PLoS One; 2014; 9(2):e89034. PubMed ID: 24586490
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.
Zhang H; Zhou W; Cao C; Zhang W; Liu G; Zhang J
PLoS One; 2018; 13(8):e0202797. PubMed ID: 30138439
[TBL] [Abstract][Full Text] [Related]
11. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
12. [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].
Chen J; Cai HW; Miao J; Xu XM; Mao W
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):703-8. PubMed ID: 27491230
[TBL] [Abstract][Full Text] [Related]
13. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation.
Gonçalves I; Edsfeldt A; Ko NY; Grufman H; Berg K; Björkbacka H; Nitulescu M; Persson A; Nilsson M; Prehn C; Adamski J; Nilsson J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1505-12. PubMed ID: 22499993
[TBL] [Abstract][Full Text] [Related]
14. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Heriansyah T; Nafisatuzzamrudah N; Aini FN; Ridwan M; Primardhika RF; Wijayanti M; Bekti RS; Wihastuti TA
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):114-119. PubMed ID: 30394217
[TBL] [Abstract][Full Text] [Related]
15. [Clinical role of lipoprotein-associated phospholipase A2].
Miklishanskaia SV; Liakishev AA; Kukharchuk VV
Kardiologiia; 2013; 53(3):59-70. PubMed ID: 23548429
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Wilensky RL; Shi Y; Mohler ER; Hamamdzic D; Burgert ME; Li J; Postle A; Fenning RS; Bollinger JG; Hoffman BE; Pelchovitz DJ; Yang J; Mirabile RC; Webb CL; Zhang L; Zhang P; Gelb MH; Walker MC; Zalewski A; Macphee CH
Nat Med; 2008 Oct; 14(10):1059-66. PubMed ID: 18806801
[TBL] [Abstract][Full Text] [Related]
17. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice.
Li RJ; Sun Y; Wang Q; Yang J; Yang Y; Song L; Wang Z; Luo XH; Su RJ
Tex Heart Inst J; 2015 Aug; 42(4):319-26. PubMed ID: 26413013
[TBL] [Abstract][Full Text] [Related]
19. [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].
Bonnefont-Rousselot D
Ann Pharm Fr; 2016 May; 74(3):190-7. PubMed ID: 26499399
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Tselepis AF; Rizzo M; Goudevenos IA
Curr Pharm Des; 2011 Nov; 17(33):3656-61. PubMed ID: 22074435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
